drug
tovorafenib
Marketedupdated 3mo agoby $DAWN Day One Biopharmaceuticals, Inc.
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying tovorafenib
- phase1A Study to Assess a Medicine Called Tovorafenib in Japanese Children and Young Adults With Brain Tumours
- phase3DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)
- phase2Tovorafenib for Treatment of Craniopharyngioma in Children and Young Adults
- phase2Study of Tovorafenib in High-Grade Glioma and Diffuse Intrinsic Pontine Glioma (DIPG)
- phase2Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors
- phase1Tovorafenib (DAY101) or in Combination With Pimasertib for Participants With Melanoma and Other Solid Tumors
- phase2A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors
- —Expanded Access Program (EAP) for Tovorafenib (DAY101) in RAF-Altered, Relapsed or Refractory Low-Grade Glioma
Patent cliff
source: FDA Orange Bookfirst barrier falls
Apr 23, 2029
~2.7 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (4)
- Jun 23, 2035formulationUS 10426782
- Jun 23, 2035formulationUS 10426782
- Aug 4, 2031compositionUS 82937525.0y
- Aug 4, 2031compositionUS 82937525.0y
FDA exclusivities (4)
- Apr 23, 2031ODE-478Orphan Drug (7y)4.7y
- Apr 23, 2031ODE-478Orphan Drug (7y)4.7y
- Apr 23, 2029NCENew Chemical Entity (5y)2.7y
- Apr 23, 2029NCENew Chemical Entity (5y)2.7y
News(1)
- Servier buys into muscular dystrophy with potentially $2.7B dealThe French drugmaker has agreed to acquire an experimental tablet from Edgewise Therapeutics that some bullish analysts say could eventually hit peak sales of over $2 billion.biopharma_dive · 2mo ago
Data sources
last refreshed 35m ago
Found something off?
comments(0)
5-min edit window · permanent after that